Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer: I'm Making My Peace With This Happy Market

Jim Cramer: I'm Making My Peace With This Happy Market

It's almost comical how welcoming it is these days.

Salix Pharmaceuticals Reports 4Q2014 And FY2014 Results

Salix Pharmaceuticals Reports 4Q2014 And FY2014 Results

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company") today announced financial and operating results for the fourth quarter and full year ended December 31, 2014.

Making My Peace With a Happy Market

It's almost comical how welcoming it is these days.

What to Expect When Salix Pharmaceuticals (SLXP) Reports Fourth Quarter Earnings Today

What to Expect When Salix Pharmaceuticals (SLXP) Reports Fourth Quarter Earnings Today

Shares of Salix Pharmaceuticals (SLXP) are down in afternoon trading ahead of the company's fourth quarter earnings report expected after the market close today.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Salix...

Salix Provides Notice Of Anticipated Make-Whole Fundamental Change To Holders Of Its 1.5% Convertible Senior Notes Due 2019

Salix Provides Notice Of Anticipated Make-Whole Fundamental Change To Holders Of Its 1.5% Convertible Senior Notes Due 2019

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (the " Company" or " Salix") today provided notice of an anticipated Make-Whole Fundamental Change to holders of its 1.

Salix Provides Notice Of Anticipated Make-Whole Fundamental Change To Holders Of Its 2.75% Convertible Senior Notes Due 2015

Salix Provides Notice Of Anticipated Make-Whole Fundamental Change To Holders Of Its 2.75% Convertible Senior Notes Due 2015

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (the " Company" or " Salix") today provided notice of an anticipated Make-Whole Fundamental Change to holders of its 2.

Finkelstein Thompson LLP Investigates Potentially Unfair Buyout Of Salix Pharmaceuticals, Ltd.

Finkelstein Thompson LLP Investigates Potentially Unfair Buyout Of Salix Pharmaceuticals, Ltd.

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals (SLXP) Stock Price Target Increased Today at Cantor Fitzgerald

Salix Pharmaceuticals (SLXP) Stock Price Target Increased Today at Cantor Fitzgerald

Shares of Salix Pharmaceuticals (SLXP) are up as Cantor Fitzgerald raises its price target to $158 from $151, while downgrading the company to 'hold' from 'buy.'

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble

Despite the many strides the market has made since 2000, critics are once again calling the Nasdaq overvalued and in 'bubble' territory. Cramer details why they're wrong.

Stocks in Wait-and-See Mode Ahead of Yellen's Congressional Address

Stocks in Wait-and-See Mode Ahead of Yellen's Congressional Address

Stocks didn't make big moves on Monday with investors preferring to wait on the sidelines ahead of key U.S. data out later in the week.

Stocks Slide as Energy Weighs; Tesla Pulls Nasdaq Lower

Stocks Slide as Energy Weighs; Tesla Pulls Nasdaq Lower

Stocks are inching lower on Monday with a selloff among energy and homebuilder stocks offsetting gains in health care.

What Investors Should Expect From Janet Yellen’s Testimony on Tuesday

What Investors Should Expect From Janet Yellen’s Testimony on Tuesday

The CNBC 'Fast Money Halftime' trading panel take a look at how stocks are likely to respond to Fed chair Janet Yellen's Senate testimony on Tuesday.

Jim Cramer Says Investors Should Buy Valeant Pharmaceuticals (VRX) After It Acquired Salix

Jim Cramer Says Investors Should Buy Valeant Pharmaceuticals (VRX) After It Acquired Salix

TheStreet's Jim Cramer discusses Valeant Pharmaceuticals' $10 billion acquisition of Salix.

4 Stocks on Traders' Radars: Salix Pharma, Ocwen and More

4 Stocks on Traders' Radars: Salix Pharma, Ocwen and More

Keep these big-volume stocks on your trading radar.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Salix Pharmaceuticals, Ltd. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Salix...

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal

Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.

Valeant Surges on Salix Acquisition: What Wall Street's Saying

Valeant Surges on Salix Acquisition: What Wall Street's Saying

Investors are cheering for Valeant Pharmaceutical's planned $14.5 billion acquisition of Salix Pharmaceuticals, but Salix shareholders were hoping for more.

Jim Cramer: Dollar General's Sales Accelerate, Valeant Is Undervalued

Jim Cramer: Dollar General's Sales Accelerate, Valeant Is Undervalued

Low gas prices mean higher sales at Dollar General and Valeant Pharmaceuticals shares appear undervalued based on its earnings potential, Cramer says.

UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Commences An Investigation Of The Board Of Directors Of Salix Pharmaceuticals, Ltd. In Connection With The Fairness Of The Sale Of The Company To Valeant Pharmaceuticals International, Inc.

UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Commences An Investigation Of The Board Of Directors Of Salix Pharmaceuticals, Ltd. In Connection With The Fairness Of The Sale Of The Company To Valeant Pharmaceuticals International, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF SALIX PHARMACEUTICALS, LTD.

SALIX ALERT: Johnson & Weaver, LLP Investigates The Fairness Of Price And Process In Proposed Sale Of Salix Pharmaceuticals To Valeant Pharmaceuticals International, Inc.

SALIX ALERT: Johnson & Weaver, LLP Investigates The Fairness Of Price And Process In Proposed Sale Of Salix Pharmaceuticals To Valeant Pharmaceuticals International, Inc.

Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Salix Pharmaceuticals, Ltd.

Stock Futures Are Mixed Following a Record-Breaking Rally

Stock Futures Are Mixed Following a Record-Breaking Rally

Stock futures are mixed on Monday morning, retreating from a record-setting rally late Friday.

February 23 Premarket Briefing: 10 Things You Should Know

February 23 Premarket Briefing: 10 Things You Should Know

U.S. stock futures look negative, although stocks ended last week at a record high.

Greek Government Under Fire at Home

And four other things you need to know now.

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

Valeant Agrees to Buy Salix Pharma for $14.5 Billion in Cash

Canada's Valeant Pharma agreed to buy Salix Pharma in cash deal valued at about $14.5 billion, the companies said Sunday.

Mario Gabelli: ‘Great Place to be Buying and Selling Stocks’

Mario Gabelli: ‘Great Place to be Buying and Selling Stocks’

The CNBC 'Fast Money Halftime' trading panel listened in on what famed investor Mario Gabelli had to say about the stock market, as well as his top stock picks.

Salix Acquisition Likely, but at What Price Is Open to Debate

Salix Acquisition Likely, but at What Price Is Open to Debate

Suitors are lining up too woo Salix Pharmaceuticals, and investors, anticipating a healthy purchase price, have pushed shares up more than 30% year-to-date.

Salix Pharmaceuticals Announces 4Q And FY2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 4Q And FY2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2014 financial results following the close of the U.

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Pre-Market Leader Stock

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a pre-market leader candidate